Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Expenses (2016 - 2025)

KalVista Pharmaceuticals' Operating Expenses history spans 11 years, with the latest figure at $55.0 million for Q2 2025.

  • On a quarterly basis, Operating Expenses rose 13.57% to $55.0 million in Q2 2025 year-over-year; TTM through Apr 2025 was $145.1 million, a 3.28% increase, with the full-year FY2025 number at $188.0 million, up 33.86% from a year prior.
  • Operating Expenses hit $55.0 million in Q2 2025 for KalVista Pharmaceuticals, up from $45.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for KALV hit a ceiling of $55.0 million in Q2 2025 and a floor of $12.7 million in Q1 2021.
  • Historically, Operating Expenses has averaged $37.3 million across 4 years, with a median of $38.7 million in 2024.
  • Biggest five-year swings in Operating Expenses: fell 11.5% in 2021 and later surged 54.01% in 2024.
  • Tracing KALV's Operating Expenses over 4 years: stood at $12.7 million in 2021, then soared by 135.02% to $29.7 million in 2023, then soared by 54.01% to $45.8 million in 2024, then grew by 20.12% to $55.0 million in 2025.
  • Business Quant data shows Operating Expenses for KALV at $55.0 million in Q2 2025, $45.8 million in Q4 2024, and $44.2 million in Q3 2024.